2x Cagrilintide 10 mg Bundle

Cagrilintide is a synthetic 37-residue amylin-analog research peptide engineered for extended half-life through C16 fatty-acid acylation. The molecule was developed to overcome the short circulating half-life of native amylin and pramlintide research peptides, enabling once-weekly research dosing schedules in laboratory research studies.

Amylin is an endogenous 37-residue peptide co-secreted with insulin from pancreatic beta-cells in research models. Amylin receptor signaling research is associated with gastric-pathway research, neuroendocrine pathways relevant to energy-balance research, and glucose-signaling research. The development of cagrilintide as a long-acting amylin analog drew on structure-activity research to balance receptor selectivity, solubility, and pharmacokinetic stability (Kruse et al., 2021, Journal of Medicinal Chemistry).

This positioning at the intersection of amylin-pathway research and long-acting peptide engineering has made cagrilintide an experimental research compound of considerable interest in laboratory research studies of amylin receptor pharmacology, combined peptide research alongside GLP-1 receptor agonists, and integrated metabolic-pathway signaling research.

1. Amylin Receptor Engagement

Cagrilintide engages amylin family receptors, which are heterodimers of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Amylin receptor signaling research is associated with gastric-pathway research, central neuroendocrine modulation relevant to energy-balance research, and glucose-signaling research models.

2. Calcitonin Receptor Interaction

Cagrilintide also engages the calcitonin receptor directly, which is investigated in research models for its role in bone-remodeling research and broader neuroendocrine-pathway research. Structural research has characterized cagrilintide binding across calcitonin and amylin receptor subtypes (Kruse et al., 2021, Journal of Medicinal Chemistry).

3. C16 Fatty-Acid Acylation

The C16 fatty-acid side chain extends the half-life of cagrilintide in research models by promoting reversible albumin binding. This enables receptor-pharmacology research at extended timepoints and supports laboratory research studies that examine long-acting amylin receptor engagement.

4. Combined Peptide Research Models

Cagrilintide is frequently investigated in combined research models alongside GLP-1 receptor agonist peptides such as semaglutide. In these laboratory research studies, dual amylin and GLP-1 receptor engagement is studied as an integrated metabolic-pathway research model, distinct from selective single-receptor agonism.

Research Applications

Conclusion

Cagrilintide represents an experimental research compound class of long-acting amylin analogs engineered through fatty-acid acylation for extended half-life in research models. By engaging amylin and calcitonin receptor subtypes, cagrilintide supports laboratory research studies of amylin receptor pharmacology and combined peptide research models, making it a valuable research target for investigations of amylin-pathway research and integrated metabolic-pathway signaling research.